Omnicare, Inc ( OCR)

Q3 2011 Earnings Call

October 25, 2011 9:00 a.m. ET


Patrick Lee – VP, IR

John Figueroa – CEO

John Workman – President and CFO


Robert Jones – Goldman Sachs

Frank Morgan – RBC Capital Markets

Jason Gurda – Leerink Swann

Lisa Gill – JPMorgan

A.J. Rice – Susquehanna Financial

Steve Halper – Stifel Nicolaus

Brendan Strong – Barclays Capital

Steven Valiquette – UBS



Good morning. My name is Lisa and I will be your conference operator today. At this time, I would like to welcome everyone to Omnicare’s Third Quarter 2011 Earnings Call. All lines have been placed on mute to prevent any background noise. After the speakers’ remarks, there will be a question-and-answer session. (Operator instructions). Thank you. I would now like to turn the call over to Patrick Lee, Omnicare’s Vice President of Investor Relations. Mr. Lee, you may begin your conference.

Patrick Lee

Thanks, Lisa. Good morning, ladies and gentlemen, and thank you for joining us today. With me on the call today are, John Figueroa, Chief Executive Officer and John Workman, President and Chief Financial Officer.

Before we begin, let me remind you that during this call, we will make remarks that constitute forward-looking statements. Actual results may differ as a result of a variety of factors including those identified in our earnings release and our various filings with the SEC. You are also cautioned that any forward-looking statements reflect management’s current views only, and that the company undertakes no obligation to revise or update such statements in the future.

Please note that this communication does not constitute an offer to buy or solicitation of an offer to sell any securities. A tender offer to purchase all issued and outstanding shares of common stock for PharMerica Corporation, is being made pursuant to a tender offer statement on schedule TO, including the offer to purchase, letter of transmittal, and other related tender offer materials that was filed on September 7, 2011 by Omnicare with the SEC.

Investors and security holders of PharMerica are able to obtain free copies of these documents and other documents filed with the SEC by Omnicare, through the website maintained by the SEC or by directly request to the corporate secretary of Omnicare.

For simplicity sake, and the focus on what we believe are the best indicators of our operating performance, we will discuss results from continuing operations and we’ll also exclude special items for all periods in our discussion today. A reconciliation of this non-GAAP information has been attached to our earnings release and is also available on our Web site. Also on our Web site, we have posted supplemental slides, which are intended to accompany our remarks this morning.

Before turning the call over to John, I would like to remind analysts to limit themselves to one question and one follow up during our question-and-answer session so others may ask their questions. With that, it is my pleasure to turn the call over to John Figueroa.

John Figueroa

Thanks Patrick, and good morning everyone, and thank you for joining us today on our call. Before we provide our prospective on our third quarter results and the key drivers behind our continued success through the start for the second half of the year, I’d like to give an update on where we stand with our $15 per-share offer for PharMerica. Following our remarks, we’ll be happy to answer your questions.

As most of you know, we recently extended our $15 per-share tender offer for PharMerica. We are pleased with the initial response from PharMerica’s investors, reflecting a 47% participation rate in that offer.

A large number of PharMerica shareholders sent a clear message that they are supportive of the offer, and would prefer our two great companies to negotiate a neutrally acceptable transaction without further delay.

While it remains our strong preference to negotiate a neutrally acceptable transaction with PharMerica, we will continue to move forward with the regulatory approval process. We are determined, but disciplined and look forward to bringing our companies together soon.

With respect to the regulatory approval process, we are working closely with the Federal Trade Commission to comply with their second request. I do not have a timeline for when we expect to complete the process at this point. However, we would not pursue a transaction unless we believe we could close expeditiously.

I believe the institutional pharmacy industry has been very competitive throughout history. And that the combination of our two company’s would not alter that.

I believe the time for the transaction of this kind is now. Any significant delay could result in both company’s losing the opportunity to realize the full strategic and cost savings benefit of such a combination. I believe it is consistent with the country’s effort to lower overall healthcare cost, and is expected to help customers manage and respond to on-going industry pressures.

And with the inherent demand within our industry, due to the aging population, I believe we have an obligation to accelerate the efficiency of our industry while improving health outcomes for the residents we serve.

Now, turning to the third quarter. We are pleased with our solid third quarter results, which reflect the progress we are making to becoming more operationally driven, and customer-focused company. We continue to execute on our operating objectives, while establishing new ones. And we remain focused on continuing to drive enhanced value for our shareholders, customers, and other important stakeholders.

For the quarter, we generated adjusted EPS of $0.54, which represented both a sequential increase and improvement from the comparable prior year period. This represents our second consecutive quarter of year-over-year growth in quarterly EPS, which underscores the continued progress we are achieving in executing our operating plan.

Our third quarter results were driven largely by an improved operating leverage with both gross margin and operating margin expanding approximately 80 basis points sequentially. We also continued to generate very robust cash flows, with cash flows from continuing operations 22% higher sequentially, and 44% greater than the third quarter of last year.

Read the rest of this transcript for free on

If you liked this article you might like

New Lifetime High Today: Omnicare (OCR)

New Lifetime High Today: Omnicare (OCR)

Omnicare (OCR) Hits New Lifetime High Today

Omnicare (OCR) Hits New Lifetime High Today

Omnicare (OCR) Hits New Lifetime High Today

Omnicare (OCR) Hits New Lifetime High Today

Don't Miss Today's Strong And Under The Radar Stock: Omnicare (OCR)

Don't Miss Today's Strong And Under The Radar Stock: Omnicare (OCR)

Barbarian At The Gate: Omnicare (OCR)

Barbarian At The Gate: Omnicare (OCR)